scPharmaceuticals has been granted a patent for a liquid pharmaceutical formulation containing furosemide, benzyl alcohol, and a pharmaceutically acceptable buffer for treating congestion, edema, fluid overload, or hypertension. The formulation has specific concentration ranges and pH levels for optimal efficacy. GlobalData’s report on scPharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on scPharmaceuticals, Nanoparticle drug conjugates was a key innovation area identified from patents. scPharmaceuticals's grant share as of May 2024 was 17%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11998555B2) discloses a liquid pharmaceutical formulation for the treatment of congestion, edema, fluid overload, or hypertension. The formulation includes furosemide or its salt, benzyl alcohol (ranging from 0.1% to 10% w/w), and a pharmaceutically acceptable buffer containing tromethamine or its salt (concentration between 25 mM to 100 mM). The concentration of furosemide in the formulation is above 40 mg/mL, with a pH range of 6.5 to 8.5. The patent also covers variations in benzyl alcohol concentration, pH range, and furosemide concentration within the formulation.
Moreover, the patent includes claims for a method of treating the mentioned conditions by administering the liquid pharmaceutical formulation through subcutaneous injection or infusion, potentially using an on-body delivery system. Additionally, a kit for the treatment of the conditions is provided, containing the unit liquid pharmaceutical formulation. The kit may include multiple units of the formulation, offering a convenient and standardized approach to treating congestion, edema, fluid overload, or hypertension. The formulations and methods outlined in the patent aim to provide an effective and consistent treatment option for patients in need of managing these medical conditions.
To know more about GlobalData’s detailed insights on scPharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
